A first-in-class reversible inhibitor of cardiac-specific myosin, mavacamten (mava; MyoKardia Inc.), was associated with significant reductions in N-terminal-pro hormone BNP (NT-proBNP) and cardiac troponin (cTnI), suggesting improved wall stress and reduced myocardial injury in non-obstructive hypertrophic cardiomyopathy (nHCM), according to study results presented Monday at the American College of Cardiology Scientific Sessions 2020 virtual conference.